Company Analysis China Biologic Products Holdings
1. Summary
Advantages
- The stock's return over the last year (0%) is higher than the sector average (-45.36%).
- Current debt level 0% is below 100% and has decreased over 5 years from 0.0619%.
Disadvantages
- Price (117.9 $) is higher than fair price (50.51 $)
- Dividends (0%) are below the sector average (0.5335%).
- The company's current efficiency (ROE=7.86%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| China Biologic Products Holdings | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -49.8% | -2.4% |
| 90 days | 0% | -43.6% | 9.8% |
| 1 year | 0% | -45.4% | 20.4% |
CBPO vs Sector: China Biologic Products Holdings has outperformed the "Healthcare" sector by 45.36% over the past year.
CBPO vs Market: China Biologic Products Holdings has significantly underperformed the market by -20.45% over the past year.
Stable price: CBPO is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CBPO with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (117.9 $) is higher than the fair price (50.51 $).
Price is higher than fair: The current price (117.9 $) is 57.2% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (31.4) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (31.4) is higher than that of the market as a whole (-78.44).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (2.3) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (2.3) is lower than that of the market as a whole (51.48).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (9.1) is lower than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (9.1) is lower than that of the market as a whole (136.11).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.65) is higher than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (15.65) is higher than that of the market as a whole (-46.89).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (7.86%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (7.86%) is higher than that of the market as a whole (-10.11%).
6.6. ROA
ROA vs Sector: The company's ROA (6.91%) is higher than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (6.91%) is lower than that of the market as a whole (39.27%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (7.43%) is higher than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (7.43%) is lower than that of the market as a whole (8.7%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5335%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
